Abstract
Types A and B Niemann–Pick disease (NPD) result from the deficient activity of acid sphingomyelinase (ASM). Currently, no treatment is available for either form of NPD. Using the ASM knockout (ASMKO) mouse model, we evaluated the effects of ex vivo hematopoietic stem cell gene therapy on the NPD phenotype. Thirty-two newborn ASMKO mice were preconditioned with low dose radiation (200 cGy) and transplanted with ASMKO bone marrow cells which had been transduced with an ecotropic retroviral vector encoding human ASM. Engraftment of donor-derived cells ranged from 15 to 60% based on Y-chromosome in situ hybridization analysis of peripheral white blood cells, and was achieved in 92% of the transplanted animals. High levels of ASM activity (up to five-fold above normal) were found in the engrafted animals for up to 10 months after transplantation, and their life-span was extended from a mean of 5 to 9 months by the gene therapy procedure. Biochemical and histological analysis of tissues obtained 4–5 months after transplantation indicated that the ASM activities were increased and the sphingomyelin storage was significantly reduced in the spleens, livers and lungs of the treated mice, major sites of pathology in type B NPD. The presence of Purkinje cell neurons was also markedly increased in the treatment group as compared with non-treated animals at 5 months after transplantation, and a reduction of storage in spinal cord neurons was observed. However, all of the transplanted mice eventually developed ataxia and died earlier than normal mice. Overall, these results indicated that hematopoietic stem cell gene therapy should be effective for the treatment of non-neurological type B NPD, but improved techniques for targeting the transplanted cells and/or expressed enzyme to specific sites of pathology in the central nervous system must be developed in order to achieve effective treatment for type A NPD.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Brady RO, Kanfer JN, Mock MB, Fredrickson DS . The metabolism of sphingomyelin. II: Evidence of an enzymatic deficiency in Niemann–Pick disease Proc Natl Acad Sci USA 1966 55: 366–369
Schneider PB, Kennedy EP . Sphingomyelinase in normal human spleens and in spleens from subjects with Niemann–Pick disease J Lipid Res 1967 8: 202–209
Schuchman EH, Desnick RJ . Niemann-Pick disease types A and B: acid sphingomyelinase deficiencies. In: Scriver CR, Beaudet A, Sly WS, Valle D (eds) The Metabolic and Molecular Basis of Inherited Disease McGraw-Hill: New York 1995 2601–2624
Schuchman EH, Suchi M, Takahashi T, Sandhoff K, Desnick RJ . Human acid sphingomyelinase: isolation, nucleotide sequence and expression of the full-length and alternatively spliced cDNAs J Biol Chem 1991 266: 8531–8539
Schuchman EH, Levran O, Pereira LV, Desnick RJ . Structural organization and complete nucleotide sequence of the gene encoding human acid sphingomyelinase Genomics 1992 12: 197–205
Horinouchi K et al. Mouse models of Niemann–Pick disease: mutation analysis and chromosomal mapping rule out the type A and B forms Genomics 1993 18: 450–451
Newrzella D, Stoffel WS . Molecular cloning of the acid sphingomyelinase of the mouse and the organization of the complete nucleotide sequence of the gene Biol Chem Hoppe Seyler 1992 373: 1233–1238
Miranda SRP, Schuchman EH . Niemann–Pick disease: mutation update, genotype/phenotype correlations, and prospects for genetic testing Gen Test 1997 1: 13–19
Horinouchi K et al. Acid sphingomyelinase deficient mice: a model of types A and B Niemann–Pick disease Nat Genet 1995 10: 288–296
Otterbach B, Stoffel W . Acid sphingomyelinase-deficient mice mimic the neurovisceral form of human lysosomal storage disease (Niemann–Pick disease) Cell 1995 81: 1053–1061
Daloze P et al. Replacement therapy for inherited enzyme deficiency: liver orthotopic transplantation in Niemann–Pick disease type A Am J Med Genet 1977 1: 229–239
Gartner JC et al. Progression of neurovisceral storage disease with supranuclear ophthalmoplegia following orthotopic liver transplantation Pediatrics 1986 77: 104–106
Scaggiante B et al. Successful therapy of Niemann–Pick disease by implantation of human amniotic membrane Transplantation 1987 44: 59–61
Vellodi A et al. Treatment of Niemann–Pick disease type B by allogeneic bone marrow transplantation Br Med J Clin Res Ed 1987 295: 1375–1376
Krivit W et al. Lysosomal storage diseases treated by bone marrow transplantation: review of 21 patients. In: Leonard JF, Pochedly C (eds) Bone Marrow Transplantation in Children Raven Press: New York 1990 pp 261–272
Bayeuer E et al. Bone marrow transplantation for Niemann–Pick type IA disease J Inherit Metab Dis 1992 15: 919–921
Miranda SRP et al. Bone marrow transplantation in acid sphingomyelinase deficient mice: engraftment and cell migration into the brain as a function of radiation, age, and phenotype Blood 1997 90: 444–452
Miranda SRP et al. Biochemical, pathological, and clinical response to transplantation of normal bone marrow cells into acid sphingomyelinase-deficient mice Transplantation 1998 65: 884–892
Hoogerbrugge PM et al. Allogeneic bone marrow transplantation for lysosomal storage diseases Lancet 1995 345: 1398–1402
Dao M, Nolta J . Molecular control of cell cycle progression in primary human hematopoietic stem cells: methods to increase levels of retrovirus-mediated transduction Leukemia 1999 13: 1473–1480
Goerner M et al. The use of granulocyte colony-stimulatingfactor during retroviral transduction on fibronectin fragment CH-296 enhances gene transfer into hematopoietic repopulating cells in dogs Blood 1999 94: 2287–2292
Chuah MK et al. Bone marrow stromal cells as targets for gene therapy of hemophilia A Hum Gene Ther 1998 9: 353–365
Eliopoulos N et al. Retroviral transfer and long-term expression of the human cytidine deaminase cDNA in hematopoietic cells following transplantation in mice Gene Therapy 1998 5: 1545–1551
Simonaro CM et al. Autologous transplantation of retrovirally transduced bone marrow or neonatal blood cells into cats can lead to long-term engraftment in the absence of myeloablation Gene Therapy 1999 6: 107–113
Kuemmel TA, Schroeder R, Stoffel W . Light and electron microscopic analysis of the central and peripheral nervous systems of acid sphingomyelinase-deficient mice resulting from gene targeting J Neuropathol Exp Neurol 1997 56: 171–179
Furuya S, Mitoma J, Makino A, Hirabayashi Y . Ceramide and its interconvertible metabolite sphingosine function as indispensable lipid factors involved in survival and dendritic differentiation of cerebellar Purkinje cells J Neurochem 1998 71: 366–377
Arnold DB, Heintz N . A calcium responsive element that regulates expression of two calcium binding proteins in Purkinje cells Proc Natl Acad Sci USA 1997 94: 8842–8847
German DC et al. Calbindin-D28k in nerve cell nuclei Neuroscience 1997 81: 735–743
Nakagawa S et al. Cytological compartmentalization in thestaggerer cerebellum, as revealed by calbindin immunohistochemistry for Purkinje cells J Comp Neurol 1998 395: 112–120
Yeyati PL et al. Fluorescent-based selection of retrovirally transduced cells in the absence of a marker gene: direct selection of transduced type B Niemann–Pick disease cells and evidence for bystander correction Hum Gene Ther 1995 6: 975–983
Markowitz D, Goff S, Bank A . Construction and use of a safe and efficient amphotropic packaging cell line Virology 1988 167: 400–406
Fillat C et al. Arylsulfatase B activities and glycosaminoglycan levels in retrovirally transduced mucopolysaccharidosis type VI cells. Prospects for gene therapy J Clin Invest 1996 98: 497–502
Huang MM et al. Retrovirus-mediated transfer of the human alpha-L-iduronidase cDNA into human hematopoietic progenitor cells leads to correction in trans of Hurler fibroblasts Gene Therapy 1997 4: 1150–1159
Markowitz D, Goff S, Bank A . A safe packaging line for gene transfer: separating viral genes on two different plasmids J Virol 1988 62: 120–124
Bertoncello I, Bartelmez SH, Bradley TR, Hogson GS . Increased Qa-m7 antigen expression is characteristic of primitive hematopoietic progenitors in regenerating marrow J Immunol 1987 139: 1096–103
Bodine DM, Seidel N, Karlsson S, Nienhius W . The combination of IL-3 and IL-6 enhances retrovirus-mediated gene transfer into hematopoietic stem cells Prog Clin Biol Res 1990 352: 287–299
Okada S et al. Enrichment and characterization of murine hematopoietic stem cells that express c-kit molecule Blood 1991 78: 1706–1712
Brugger W et al. Ex vivo expansion of enriched peripheral blood CD34+ progenitor cells by stem cell factor, interleukin-1 beta (IL-1 beta), IL-6, IL-3, interferon-gamma, and erythropoietin Blood 1993 81: 2579–2584
Koller MR, Bender JG, Miller WM, Papoutsakis ET . Expansion of primitive human hematopoietic progenitors in a perfusion bioreactor system with IL-3, IL-6, and stem cell factor Biotechnology 1993 11: 358–363
Singh L, Panicker SG, Nagaraj R, Majundar KC . Banded krait minor-satellite (Bkm)-associated Y chromosome specific repetitive DNA in mouse Nucleic Acid Res 1994 22: 2289–2295
Dinur T et al. Toward gene therapy for Niemann–Pick disease (NPD): separation of retrovirally corrected and non-corrected NPD fibroblasts using a novel fluorescent sphingomyelin Hum Gene Ther 1992 3: 633–640
Stein S et al. Amino acid analysis with fluorescamine at the picomole level Arch Biochem Biophys 1973 155: 202–209
Schissel SL, Schuchman EH, Williams KJ, Tabas I . Zn2+-stimulated sphingomyelinase is secreted by many cell types and is a product of the acid sphingomyelinase gene J Biol Chem 1996 271: 18431–18439
Rousseau A, Livni N, Gatt S . Utilization of membranous lipid substrates by membranous enzymes: activation of the latent sphingomyelinase of hen erythrocyte membrane Arch Biochem Biophys 1986 244: 838–844
Acknowledgements
This work was supported by research grants from the National Institute of Health (HD 28607 and HD 32654), March of Dimes Birth Defects Foundation (1–2224), a grant (RR 0071) from the National Center for Research Resources for the Mount Sinai General Clinical Research Center, and a grant (93–00015) from the US–Israel Binational Science Foundation. We would like to thank Dr Lalji Singh, from the Center for Cellular and Molecular Biology (India), for providing the Y chromosome-specific probe.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Miranda, S., Erlich, S., Friedrich, V. et al. Hematopoietic stem cell gene therapy leads to marked visceral organ improvements and a delayed onset of neurological abnormalities in the acid sphingomyelinase deficient mouse model of Niemann–Pick disease. Gene Ther 7, 1768–1776 (2000). https://doi.org/10.1038/sj.gt.3301300
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3301300
Keywords
This article is cited by
-
Experimental neurotransplantation treatment for hereditary cerebellar ataxias
Cerebellum & Ataxias (2016)
-
The pathogenesis and treatment of acid sphingomyelinase‐deficient Niemann–Pick disease
Journal of Inherited Metabolic Disease (2007)
-
Gene therapy progress and prospects: gene therapy of lysosomal storage disorders
Gene Therapy (2003)
-
Enzyme replacement and enhancement therapies: lessons from lysosomal disorders
Nature Reviews Genetics (2002)